Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.
- Address
- Ul. Studzienna 35-36/a, 82-300 Elblag, Poland
Immune System Diseases
The centre is running studies that target autoimmune conditions such as severe alopecia areata and active axial spondyloarthritis, aiming to evaluate new oral therapies that modulate the immune response.
- Efficacy of upadacitinib in severe alopecia areata
- Assessment of filgotinib for active axial spondyloarthritis
- Long‑term safety monitoring of JAK inhibitor treatment
Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p. leverages its expertise to bring innovative treatment options to patients with immune‑mediated diseases.
Musculoskeletal Diseases
Research at the site focuses on joint‑related disorders, including knee osteoarthritis and axial spondyloarthritis, with the goal of improving pain control, function, and disease progression through novel therapeutic approaches.
- Evaluation of new agents for knee osteoarthritis symptom relief
- Investigation of disease‑modifying potential in axial spondyloarthritis
- Integration of metabolic health strategies with musculoskeletal outcomes
The Elbląg facility supports patients by advancing treatments that address the physical challenges of musculoskeletal conditions.
Nutritional and Metabolic Diseases
The institution conducts trials aimed at tackling obesity and overweight, testing innovative compounds designed to promote weight loss and improve metabolic health, often in conjunction with related comorbidities.
- Testing retatrutide for effective weight reduction
- Assessing metabolic impact of emerging anti‑obesity therapies
- Combining weight‑loss interventions with joint health assessments
By participating in these studies, the centre contributes to the development of safer and more effective solutions for metabolic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Janssen Cilag International3active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International9trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.
lock Showing 1 of 49 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Jnj-77242113 | 6 | Unknown | 2023-12-05 | 2025-05-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.